


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



康宁

Wenzhou Kangning Hospital Co., Ltd.

溫州康寧醫院股份有限公司

(a joint stock limited company incorporated in the People's Republic of China)

(Stock Code: 2120)

Wenzhou Kangning Hospital Co., Ltd.
(溫州康寧醫院股份有限公司)

- 1.1 The board of directors (the **Board**) of Wenzhou Kangning Hospital Co., Ltd. (the **Company**) is pleased to announce the interim result of the Company and its subsidiaries (collectively, the **Group**) for the interim month ended June 30, 2016 (the **Interim Month**) in comparison with the figures for the interim month ended June 30, 2015.
- 1.2 The condensed consolidated financial information of the Group for the Reporting Period (the **Reporting Period**) is prepared in accordance with the International Financial Reporting Standards (the **IFRS**).

	2015
	RMB'000
	(Audited)
Revenue	160,743
Profit before income tax	37,086
Income tax expense	(9,732)
Total comprehensive income	27,354
Total comprehensive income attributable to equity holders of the Company	29,130
Non-controlling interest	(1,776)
	As of
	December 31,
	2015
	RMB'000
	(Audited)
Total assets	1,224,434
Total liabilities	262,205
Total equity	962,229
Equity attributable to owners of the Company	959,716
Non-controlling interest	2,513

2016年12月31日

In the first half of 2016, the People's Republic of China (the "PRC") continued to promote the reform of the healthcare system. While continuing to enhance the operational capabilities of a new type of healthcare facilities, the implemented certain mid- and long-term development strategies to lay a foundation for the long-term development of the Company. Details of the progress we have made are as follows:

In April and May 2016, Linhai Kangning Hospital (臨海康寧醫院) and Wenzhou Yining Geriatric Hospital (溫州怡寧老年醫院) (collectively, the "Hospitals") commenced operation, and achieved satisfactory results in terms of utilization rate of hospital beds in a short period. On March 31, 2016, the officially managed Pujiang Huangfeng Psychiatric Special Hospital (浦江黃鋒精神專科醫院) (collectively, the "Hospitals") and Chuan'an Huangfeng Kang'en Hospital (淳安黃鋒康恩醫院) (collectively, the "Hospitals") have been engaged in cooperation to provide capital and provide management and

consultancy service. Furthermore, pursuant to the Company's 2015 annual report published on April 29, 2016. As of the end of June 2016, the number of the Group's healthcare facilities increased to 13, and the number of beds in operation increased to 3,000.

We also see a new focus on the long-term development of the Company. During the Reporting Period, the Company entered into a framework agreement with Wenzhou Medical University (温州医科大学) in relation to the proposed establishment and operation of the Psychiatric School of Wenzhou Medical University (温州医科大学精神医学学院). The school was established on March 20, 2016 and is scheduled to have 60 undergraduate students and 30 graduate students majoring in psychiatry, and 30 undergraduate students majoring in applied psychology will be enrolled in August 2016.

In order to further promote merger and acquisition strategy for the future development of the Company, on February 22, 2016, the Company entered into a partnership agreement with, among others, Shanghai Jinpu Jianfeng Equity Investment Management Co., Ltd. (上海金浦健服股权投资管理有限公司, 简称“金浦健服”) in relation to the Company's contribution of RMB50.0 million for the establishment of the Chongqing Jinpu Healthcare Service Industrial Equity Investment Fund L.P. (重庆金浦医疗健康服务产业股权投资基金合伙企业(有限合伙)), the Chongqing Jinpu Healthcare Service Industrial Equity Investment Fund L.P. (重庆金浦医疗健康服务产业股权投资基金合伙企业(有限合伙)). On the same date, the Company and Jinpu Jianfeng, the managing partner of the Investment Fund, entered into a strategic cooperation agreement in relation to, among others, the strengthening of the Company's limited partner of the Investment Fund. Furthermore, pursuant to the Company's announcement dated February 23, 2016. The Investment Fund was established in the PRC on March 22, 2016.

In addition, during the Reporting Period, Didi Psychology (的的心理), an online psychological consultation platform which the Company entered into and developed, was officially launched and progressed a made in making. As of June 30, 2016, 92 psychiatrists and 227 psychological consultants were recruited, upon examination and approval, and 1,578 cases of psychological consultation were completed through the platform. We will further optimize the function of Didi Psychology and enhance service experience.

Looking into the future, we will also speed up the preparation for the opening of Pingyang Kangning Hospital (平陽康寧醫院), Quzhou Yining Hospital (衢州怡寧醫院) and Shenzhen Yining Hospital (深圳怡寧醫院), aiming for them to commence operation in the second half of 2016. Meanwhile, the healthcare e-commerce platform of the Entrepreneurial Program for 100 People (百人創業計劃) was launched at the beginning of 2016. We will also accelerate the expansion of the healthcare facilities network of the Group through integrating resources.

The Group achieved a net income of RMB189.1 million during the Reporting Period, representing an increase of 17.6% as compared with that of the same period of 2015. The net income from operating the Group's owned hospital and hospital management service fee from managing healthcare facilities both increased. The gross profit margin of owned hospital decreased to 36.0%, and the gross profit margin of healthcare facilities management business was 51.1%. The overall gross profit margin of the Group during the Reporting Period decreased to 36.7% (in month ended June 30, 2015: 40.6%) due to the utilization rate of new facilities. During the Reporting Period, net property available to shareholders amounted to RMB28.2 million, representing a decrease of 3.2% as compared with that of the same period of 2015.

4.1.1 **Operating Income**

The Group generated net income mainly through the following sources: (i) net income from operating owned hospital, and (ii) management service fee from managing healthcare facilities.

The table below sets forth a breakdown of total net income for the period indicated:

	2015	
	(in RMB'000)	(RMB'000)
		(Audited)
Net income from operating the Group's owned hospital	155,169	
Management service fee income	5,574	
Total net income	160,743	

During the Reporting Period, total revenue of the Group amounted to RMB189.1 million, representing an increase of 17.6% as compared with that of the same period of 2015, primarily due to (i) the increase of revenue from operating the Group's owned hospitals by 16.2% and (ii) the increase of management service fee income by 58.5%. Revenue from operating the Group's owned hospitals accounted for 95.3% of total revenue (in month ended June 30, 2015: 96.5%) and management service fee income accounted for 4.7% of total revenue (in month ended June 30, 2015: 3.5%).

Revenue and cost of revenue from operating the Group's owned hospitals

Revenue from operating the Group's owned hospitals consist of fee charged for the outpatient visit and the inpatient service at a hospital, including treatment and general healthcare service, pharmaceutical sale and ancillary hospital service. The table below sets forth a breakdown of revenue and cost of revenue from operating the Group's owned hospitals for the period indicated:

	2015 (in RMB'000)	2015 (in RMB'000) (Audited)
Treatment and general healthcare service	111,945	
Pharmaceutical sale	42,227	
Ancillary hospital service	997	
Total revenue	155,169	
Cost of revenue	94,115	
Gross profit	61,054	

During the Reporting Period, revenue from the Group's owned hospitals amounted to RMB180.3 million, representing an increase of 16.2% as compared with that of the same period of 2015.

The table below is for a breakdown of the expense of the Group's operational business and capital expenditure for the period indicated, in the accompanying data:

	2015
Inpatient	
Inpatient bed at period end	1,913
Effective inpatient service bed-d capacity	346,253
Utilization rate (%)	95.0%
Number of inpatient bed-d	328,893
Team and general healthcare service expense attributable to inpatient (RMB'000)	104,964
Age inpatient pending per bed-d on team and general healthcare service (RMB)	319
Pharmaceutical expense attributable to inpatient (RMB'000)	18,963
Age inpatient pending per bed-d on pharmaceutical (RMB)	58
Total (RMB'000)	123,927
Capital	
Number of capital	60,944
Team and general healthcare service expense attributable to capital (RMB'000)	6,981
Age capital pending per on team and general healthcare service (RMB)	115
Pharmaceutical expense attributable to capital (RMB'000)	23,264
Age capital pending per on pharmaceutical (RMB)	382
Total (RMB'000)	30,245

		2015
Interest income on deposits		
(— B)		497
Interest income on loans		
(— B'000)		111,945
Interest income on other financial assets		
(— B'000)		42,227

During the Reporting Period, interest income amounted to RMB143.7 million, representing an increase of 16.0% as compared with that of the same period of 2015, primarily due to (i) the increase of interest income by 12.7% and (ii) the increase of average interest income pending period by 2.9%. Interest income accounted for 79.7% of all income from operating activities (in month ended June 30, 2015: 79.9%).

During the Reporting Period, commission income amounted to RMB35.3 million, representing an increase of 16.6% as compared with that of the same period of 2015, primarily due to (i) the increase of commission by 13.0% and (ii) the increase of average commission pending period by 3.0%. Commission income accounted for 19.6% of all income from operating activities (in month ended June 30, 2015: 19.5%).

During the Reporting Period, due to the increase of both interest and commission income, the income from fees and general healthcare service increased by 15.6% as compared with that of the same period of 2015, accounting for 71.8% of all income from operating activities (in month ended June 30, 2015: 72.1%); and the income from pharmaceutical sales increased by 17.4% as compared with that of the same period of 2015, accounting for 27.5% of all income from operating activities (in month ended June 30, 2015: 27.2%).

Cost of expense of the owned hospital of the Group primarily consisted of pharmaceutical and consumable used, employee benefit and expense, leasing expense, depreciation and amortization, cancellation expense and testing fee. The table below sets forth a breakdown of cost of expense for operating the Group's owned hospital for the period indicated:

	2016	2015
	(RMB'000)	(RMB'000)
	(Audited)	(Audited)
Pharmaceutical and consumable used	41,266	
Employee benefit and expense	33,343	
Leasing expense	3,352	
Depreciation and amortization	6,706	
Cancellation expense	4,399	
Testing fee	1,590	
Other	3,459	
Cost of expense	94,115	

During the Reporting Period, the cost of expense of the Group's owned hospital increased to RMB115.3 million, representing an increase of 22.5% as compared with that of the same period of 2015, which was higher than the increase of expense. It is mainly due to: (i) the increase of 16.5% in pharmaceutical expense relating to increase in expense from pharmaceutical sale; (ii) the increase of 19.5% in employee benefit and expense arising from the increase in bed in operation of owned hospital; (iii) the added leasing expense and depreciation and amortization of RMB0.9 million of Linhai Kangning Hospital which was newly put in operation in 2016.

From the cost components, the percentage, pharmaceutical and consumable, is still the main part of the cost of the owned hospital, accounting for 41.7% (in month ended June 30, 2015: 43.8%). The second part is employee benefit and expense, which accounted for 34.6% of the cost of the owned hospital (in month ended June 30, 2015: 35.4%). Leaving expense, other depreciation and amortization, accounted for 10.3% of the cost of the owned hospital (in month ended June 30, 2015: 10.7%).

Management service fee income

The Group's management service fee income is primarily derived from ending management service of the healthcare facilities. The table below shows the breakdown of management service fee income and cost for the period indicated:

	2015 (in RMB'000) (Audited)
Revenue	5,574
Cost of revenue	1,390
Gross profit	4,184

During the Reporting Period, management service fee income of the Group amounted to RMB8.8 million, representing an increase of 58.5% as compared with that of the same period of 2015 and accounting for 4.7% of the total revenue of the Group, due to the contribution of the management service fee in relation to the newly-opened Beijing Yining Hospital (北京怡寧醫院) in the second half of 2015 and R Jiang Hospital and Chunan Hospital starting from April 1, 2016. As of June 30, the Group managed 6 healthcare facilities, with 700 beds in operation.

Cost of the Group for ending management service primarily include benefit and expense for management staff assigned and amortization of operation right acquired for obtaining management right.

Cost of the management service increased to RMB4.3 million, representing an increase of 210.7% as compared with that of the same period of 2015, accelerating the increase of the expense, mainly because in April 2015, the commenced management of Yanjiao Furen Hospital of Traditional Chinese and Western Medicine (燕郊輔仁中西醫結合醫院) (燕郊輔仁中西醫結合醫院). The Group acquired 19 shares and 9 months of operation right of this hospital and recognized RMB93.1 million of intangible assets. RMB2.4 million was amortized for the operation right during the Reporting Period (11 months ended June 30, 2015: 1.2 million). Accordingly, gross profit margin decreased to 51.1% (11 months ended June 30, 2015: 75.1%).

4.1.2 4.1.2 4.1.2 4.1.2 4.1.2 4.1.2 4.1.2 4.1.2 4.1.2 4.1.2

During the Reporting Period, total gross profit of the Group amounted to RMB69.5 million, representing an increase of 6.5% as compared with that of the same period of 2015. Overall gross profit margin decreased to 36.7% (11 months ended June 30, 2015: 40.6%), mainly due to (i) the decrease in gross profit margin of the Group's owned hospital as a result of loss utilization rate of bed of Linhai Kangning Hospital and Geriatric Hospital which have been opened in April and May 2016, respectively; and (ii) since Yanjiao Furen Hospital was unable to make profit, the did not recognize any management service fee according to the management agreement which had a negative impact on the gross profit margin of the management and service business.

Additionally, the gross profit margin of pharmaceutical sales was 17.6% for the Reporting Period (11 months ended June 30, 2015: 18.3%).

4.1.3 4.1.3 4.1.3 4.1.3 4.1.3 4.1.3 4.1.3 4.1.3 4.1.3 4.1.3

The income of the Group consisted of government grants and interest income. During the Reporting Period, the income amounted to RMB3.0 million, representing an increase of 3,096.8% as compared with that of the same period of 2015, primarily due to the increase in interest income from deposits.

4.1.4 Selling expense

During the Reporting Period, the selling expense of the Group amounted to RMB1.0 million (in month ended June 30, 2015: RMB0.5 million), representing an increase of 97.3% as compared with that of the same period of 2015, mainly due to the increase in promotion expense of the newly-opened Linhai Kangning Hospital and Geiaic Hospital in April and May 2016, respectively.

4.1.5 Administrative expense

Administrative expense of the Group primarily consists of benefits and expense for the management and administrative affairs, expense of the newly-built hospital prior to the commencement of operation, depreciation, amortization and others. The table below sets forth a breakdown of administrative expense for the period indicated:

	2016 (in RMB'000)	2015 (RMB'000) (Audited)
Employee benefits and expense	8,542	
Leasing expense	7,765	
Depreciation and amortization	2,096	
Selling expense	772	
Contingency expense	200	
Donation	823	
Provision for impairment of receivable	2,961	
Others	3,430	
Total administrative expense	<u>26,589</u>	

During the Reporting Period, administrative expenses of the Group amounted to RMB39.6 million (in month ended June 30, 2015: RMB26.6 million), representing a substantial increase of 49.0% as compared to the same period of 2015, primarily due to: (i) an increase of RMB6.7 million in employee benefits and expenses attributable of the increase in (1) administration, research and information technology staff and (2) administrative staff for the opening of Linhai Kangning Hospital and Geiaic Hospital; (ii) an increase of RMB1.3 million in the consolidated expense for meeting the listing requirements after the listing of the Company; and (iii) expense primarily related to developing and promoting Didi Psychology online platform increased by RMB3.4 million. During the Reporting Period, the proportion of administrative expenses to total expense of the Group increased to 20.9% (in month ended June 30, 2015: 16.5%).

4.1.6 Financial Income and Expenses

Our finance income includes interest income from bank deposits and the gain on foreign exchange, and the finance expense includes the interest expense on bank loan and the financial expense in relation to long-term payable. The table below sets forth a breakdown of our financial income and expense for the period indicated:

		2015 (in RMB'000)	(RMB'000) (Audited)
Interest income	307		
Exchange gain	B		
Finance income	307		
Finance expense	(1,334)		
Finance income/expense Bne	(1,027)		

During the Repo-ing Period, the net finance income of the Group increased to RMB7.7 million, primarily attributable to (i) the increase of RMB0.6 million in the net income of the proceeds from the initial public offering deposited in the bank, and (ii) the increase in the exchange gain of RMB9.6 million arising from the higher exchange rate of Hong Kong dollar against RMB due to the fact that the proceeds from the initial public offering were deposited in Hong Kong dollar. Finance expense mainly comprised the finance expense of RMB2.8 million measured at the effective interest rate from the long-term payable in relation to the entered management of Yanjiao Financial Holdings, representing an increase of 108.4% as compared with the same period of 2015, primarily because we entered into the management of Yanjiao Financial Holdings in April 2015 and the same period of 2015 only included the month of interest calculation accordingly.

4.1.7 *Other income and expenses* A

During the Repo-ing Period, the effect of income tax accounted for during the equity method amounted to RMB2.2 million (for the month ended June 30, 2015: nil), representing a 49% equity income in Beijing Yining Holdings, which commenced operation in September 2015 and recorded loss after tax of RMB4.5 million during the Repo-ing Period.

4.1.8 *Other income and expenses*

During the Repo-ing Period, income and expense increased to RMB10.5 million, representing an increase of 8.2% as compared with the same period of 2015, primarily due to the fact that deferred income tax expense not recognized for loss of Hangzhou Honglan Information Technology Co., Ltd. (杭州宏澜信息科技有限公司) (宏澜信息) of the period. For the month ended June 30, 2015 and 2016, actual rate were 26.2% and 28.6%, respectively. The increase in actual rate for the Repo-ing Period is mainly due to the increase in fee not deducted before.

4.1.9 4.1.9 4.1.9 4.1.9 4.1.9

During the Reporting Period, total comprehensive income attributable to one of the Companies amounted to RMB28.2 million, representing a decrease of 3.2% as compared with the same period of 2015, primarily due to the following reasons:

- (i) The expense of developing and promoting the online psychological consultation platform increased by RMB3.4 million;
- (ii) Geriatric Hospital, which commenced operation in March 2016, recorded loss after tax of RMB3.3 million;
- (iii) Linhai Kangning Hospital, which commenced operation in April 2016, recorded loss after tax of RMB3.0 million;
- (iv) Purchase of land of investmentmen accounted for using the equity method increased by RMB2.2 million, due to after tax loss of RMB4.5 million of Beijing Yining Hospital; and
- (v) Cost and expense relating to managing Yanjiao Ren Hospital increased by RMB3.2 million.

4.2.1 4.2.1 4.2.1 4.2.1 4.2.1

As of June 30, 2016, inventory balance increased to RMB9.3 million (as of December 31, 2015: RMB7.5 million), primarily due to the increase in pharmaceutical inventory of newly-opened Linhai Kangning Hospital and Geriatric Hospital.

4.2.2 4.2.2 4.2.2 4.2.2 4.2.2

As of June 30, 2016, the balance of receivable slightly increased to RMB129.5 million (as of December 31, 2015: RMB123.1 million), primarily due to: (i) the increase in accounts receivable of the same period in line with the business growth of the healthcare facilities; and (ii) the increase in the amount of receivable attributable to medical insurance program. Approximately 70.0% of the receivable of the Group is the bill not presented or aged within 1 month.

4.2.3 其他應收款

As of June 30, 2016, other receivable, deposits and prepayments increased to RMB109.7 million (as of December 31, 2015: RMB91.0 million), primarily due to deposits of RMB38.1 million relating to the acquisition of equity interest in Wenzhou Guoda Investment Company (溫州國大投資有限公司) (溫州國大) and the credit worthiness held by Guoda Investment's certain creditors. For details, please refer to the Company's announcement dated June 2, 2016.

4.2.4 可供出售金融資產

As of June 30, 2016, available-for-sale financial assets balance increased by RMB50.0 million, primarily due to our contribution to the Investment Fund. For details, please refer to the Company's announcement dated February 23, 2016.

4.2.5 應付賬款

As of June 30, 2016, payable increased to RMB30.3 million (as of December 31, 2015: RMB20.0 million), of which approximately 90.6% aged within 90 days.

4.2.6 其他應付款

As of June 30, 2016, accrual and other payable decreased to RMB164.3 million (as of December 31, 2015: RMB166.4 million).

The table below sets forth the information as extracted from the condensed consolidated cash flow statement of the Group for the period indicated:

	2015 (in RMB'000) (Audited)
Net cash generated from/(used in) operating activities	(14,018)
Net cash used in investing activities	(60,982)
Net cash generated from financing activities	77,553
Net (decrease)/increase in cash and cash equivalents	2,553

4.3.1 *Net cash generated from/(used in) operating activities* / *As of June 30, 2016*

During the month ended June 30, 2016, net cash generated from operating activities amounted to RMB38.0 million. We had net cash generated from operating activities before change in working capital of RMB44.5 million, primarily consisting of profit before tax of RMB36.8 million and adjustment for depreciation of property, plant and equipment of RMB10.2 million. Change in working capital resulted in cash inflow of RMB7.1 million. We had cash flow of RMB13.6 million attributable to income tax paid.

4.3.2 *Net cash used in investing activities* / *As of June 30, 2016*

During the Reporting Period, net cash used in investing activities amounted to RMB159.0 million, primarily due to: (i) purchase of property, plant and equipment and intangible assets of RMB71.4 million, consisting of (1) amount paid and prepaid to Wenzhou Kangning Hospital, (2) amount paid to Wenzhou Kangning Hospital for the purchase of Pingyang Kangning Hospital; and (ii) RMB50.0 million for the contribution to the Investment Fund.

4.3.3 *Financing of the Company's operations*

During the Reporting Period, net cash generated from financing activities amounted to RMB22.1 million, primarily due to a loan of RMB50.0 million from China CITIC Bank, which offset repayment of the loan of RMB30.0 million from China CITIC Bank.

4.3.4 *Capital structure and capital management*

On February 22, 2016, the Company entered into a strategic cooperation agreement to contribute RMB50.0 million to the Invention Fund, which shall invest in healthcare and other modern service industries. In principle, the Invention Fund's investment in the healthcare service industry shall be no less than 80% of its total amount available for investment. Please refer to the announcement of the Company dated February 23, 2016 for details.

On June 2, 2016, the Company entered into an agreement with Wenzhou Medical University Asset Management Company Limited* (温州医科大学资产经营有限公司, the "Wenzhou Medical University Asset Management Company") and Wenzhou Medical University in relation to (i) the acquisition of 51% of the equity interest in Guda Invention by the Company from the Vendor and (ii) the acquisition by the Company of Wenzhou Medical University's credit right in relation to certain amount of debt of Guda Invention. The Company shall pay the consideration for the acquisition of equity interest of approximately RMB17.5 million and pay the consideration for the acquisition of credit right of approximately RMB20.6 million. Please refer to the announcement of the Company dated June 2, 2016 for details.

Save as disclosed above, the Group had no other significant investment, acquisition or disposal during the month ended June 30, 2016.

4.4.1 *Bank balances*

As of June 30, 2016, the balance of bank borrowing of the Group amounted to RMB70.0 million (as of December 31, 2015: RMB50.0 million), primarily attributable to the additional borrowing of RMB50.0 million designated for construction purpose and the repayment of borrowing of RMB30.0 million as working capital in the meantime during the Reporting Period. The bank borrowing decreased by one year amount to RMB20.0 million, while bank borrowing decreased by one year amount to RMB50.0 million.

* For identification purposes only

4.4.2 截至2016年6月30日

As of June 30, 2016, the Group had no contingent liabilities or guarantee that would have a material impact on the financial position or operation of the Group.

4.4.3 资产抵押

As of June 30, 2016, none of the Group's assets had been pledged.

4.4.4 合同义务

The contractual obligation of the Group primarily consists of operating lease and agreements. As of June 30, 2016, the future aggregate minimum lease payments under non-cancellable lease agreements were RMB194.7 million.

✎

4.4.5 金融资产

Financial instruments of the Group consist of trade receivable, available-for-sale financial assets, amounts due from related parties, other receivable, employee deposits, cash and cash equivalents, bank borrowings, due and other payable. The Company's management manages and monitors the exposure to interest rate effective measures are implemented on a timely manner.

✎

✎

4.4.6 外币金融资产及金融负债

The Group deposits certain of its financial assets in foreign currencies, which mainly include risk of fluctuation in the exchange rate of Hong Kong dollar against Renminbi. The Group is exposed to foreign exchange risk accordingly.

During the month ended June 30, 2016, the Group has not used any derivative financial instrument to hedge against the exposure to currency risk. The management of the Company manages the currency risk by closely monitoring the movement of the foreign exchange rate and will consider hedging against significant foreign exchange exposure which need arise.

✎

4.4.7 公允价值

As of June 30, 2016, the Group's gearing ratio (total interest-bearing liabilities divided by total assets) was 12.7% (as of December 31, 2015: 11.8%).

During the Reporting Period, neither the Company nor any of its subsidiaries purchased, sold or redeemed any of the Company's listed securities.

The Company's audit committee has reviewed the Group's financial statements in relation to the interim financial statements ended June 30, 2016 and has opined that applicable accounting standards and requirements have been complied with and that adequate disclosures have been made by the Company.

The Company's audit committee consists of two independent non-executive directors of the Company, Mr. HUANG Zhi (the chairman of the audit committee of the Company) and Mr. GOT Chong Ke Clein, and one non-executive director of the Company, Mr. HE Xin. Among them, Mr. HUANG Zhi has the appropriate professional qualification (a certified public accountant accredited by the Chinese Institute of Certified Public Accountants (中國註冊會計師協會)).

The Board does not recommend the payment of an interim dividend for the interim period ended June 30, 2016 (for the interim period ended June 30, 2015: nil).

The Company has complied with all code provisions in the Corporate Governance Code set out in Appendix 14 of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited during the Reporting Period.

The accounting policies applied are consistent with those of the annual financial statements for the year ended December 31, 2015, as described in those annual financial statements except for the adoption of amendments to IFRS effective for the financial year ending December 31, 2016 and the accounting policy for available-for-sale financial assets, which is newly applied to a new transaction in 2016.

The Condensed Consolidated Interim Financial Information of the Group prepared in accordance with the IFRS is set out as follows:

8.2.1 Condensed Consolidated Interim Profit Statement

	2015 RMB'000 (Audited)
Revenue	160,743
Cost of revenue	(95,505)
Operating profit	65,238
Other income	93
Other losses	(113)
Selling expenses	(516)
Administrative expenses	(26,589)
Finance income/(expenses) Net	(1,027)
Share of losses of investees accounted for using the equity method	B
Income before income taxes	37,086
Income tax expense	(9,732)
Other comprehensive income	27,354 B
Profit attributable to equity holders of the Company	27,354
Profit attributable to non-controlling interests	
Attributable to:	
BEquity holders of the Company	29,130
BNon-controlling interests	(1,776)
Basic and diluted earnings per share (in RMB)	0.57

8.2.2 2015年12月31日合并资产负债表

	人民币千元 RMB'000	December 31, 2015 RMB'000 (Audited)
流动资产		
货币资金	233,200	233,200
应收账款	20,738	20,738
预付款项	90,581	90,581
其他应收款	8,422	8,422
存货	10,071	10,071
可供出售金融资产		
持有待售资产	48,324	48,324
流动资产合计	411,336	411,336
非流动资产		
长期股权投资	7,506	7,506
固定资产	123,067	123,067
在建工程	42,690	42,690
无形资产	20,044	20,044
递延所得税资产	251,334	251,334
其他非流动资产	368,457	368,457
非流动资产合计	813,098	813,098
资产总计	1,224,434	1,224,434
流动负债		
短期借款		
应付账款	73,040	73,040
预收款项	797,510	797,510
应付职工薪酬	11,342	11,342
应交税费	77,824	77,824
其他应付款	959,716	959,716
流动负债合计	2,513	2,513
非流动负债		
长期借款	962,229	962,229

December 31,
2015
RMB'000
(Audited)

Bank borrowing		B
Deferred government grants	14,284	
Long-term payable	98,821	
	<u>113,105</u>	
Bank borrowing		50,000
Trade payable	19,976	
Accrual and other payable	63,209	
Dividend payable		B
Government income liability	11,559	
Government portion of long-term payable	4,356	
	<u>149,100</u>	
	<u>262,205</u>	
	<u>1,224,434</u>	

		Attributable to the Company					
		Share Capital	Capital Reserve	Surplus	Retained Earnings	Total	Non-controlling interest
Note		RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
	At the beginning of the year	50,000	159,153	5,708	46,229	261,090	B
	During the year						
	Issuance of shares	B	B	B	29,130	29,130	(1,776)
	Total share issue, recognized decline in equity						
	Capital contribution by shareholders	15	2,800	75,600	B	B	78,400
	Employee share option scheme:						
	Value of employee service	16	B	1,031	B	1,031	B
	Dividend payable in 2014	25	B	B	(18,480)	(18,480)	B
	Capital contribution by non-controlling interest		B	B	B	B	2,400
	At the end of the year	2,800	76,631	B	(18,480)	60,951	2,400
	At the beginning of the year	52,800	235,784	5,708	56,879	351,171	624

8.2.4 2015 年 12 月 31 日 2015 年 12 月 31 日

	2015 RMB'000 (Audited)
Capital generated from operation	2,670
Income tax paid	(16,688)
	(14,018)
Change of property, plant and equipment	(49,279)
Change of intangible assets	(10)
Proceed from transfer of construction in progress	B
Change of available-for-sale assets	B
Payments of dividends	B
Amounts withheld payable	(12,000)
Interest received	307
	(60,982)
Proceed of borrowing	B
Repayment of borrowing	B
Payments for H share IPO cost	(5,247)
Payments for A share IPO cost	B
Proceed from capital contribution by shareholders	78,400
Deposits received from a non-controlling interest	2,000
Share capital received from a non-controlling interest	2,400

	2015 RMB'000 (Audited)
Trade receivable	77,553
Less: provision for impairment of trade receivable	2,553
Carrying amount of trade receivable at beginning of the period	37,271
Exchange gain on trade receivable	8
Carrying amount of trade receivable at end of the period	39,824

8.3.1 Trade receivable

	December 31, 2015 RMB'000 (Audited)
Trade receivable	130,738
Less: provision for impairment of trade receivable	(7,671)
Trade receivable Net	123,067

The carrying amount of the Group's trade receivable is denominated in RMB and approximate to the fair value.

As of June 30, 2016 and December 31, 2015, the ageing analysis of the receivable is as follows:

	December 31, 2015
	RMB'000
	(Audited)
Aging analysis based on the billing date:	
Bill not entered	9,580
1-3 months	74,718
4-6 months	19,635
7-12 months	19,937
1-2 years	5,075
2-3 years	1,426
over 3 years	367
	<u>130,738</u>

According to the Group's experience of business, all bills are payable upon presentation.

8.3.2 Other receivables

	December 31, 2015
	RMB'000
	(Audited)
Other receivable (a)	14,337
Deposits (b)	17,268
Amounts withheld payable (c)	12,304
Payments for rental	30,007
Deposits for investments	
in subsidiaries (d)	B
Payments for purchase of property	13,000
Payments for construction in progress	2,594
Payments for good and service	2,539
Other	43
Less: provision for impairment of other receivable	(1,078)
Total	<u>91,014</u>

		December 31, 2015
	RMB'000	RMB'000 (Audited)
Guarantee		42,690
Non-Guarantee		48,324
Total		91,014

The carrying amount of the Group's receivable, deposit and prepayment are denominated in RMB and approximate their fair value.

- (a) Included in the receivable as of June 30, 2016 is an advance payment amounting to RMB3,321,000 (as of December 31, 2015: RMB9,210,000) to Yanjiao Fintech Co., Ltd. Such advance will be repaid to the Group by Yanjiao Fintech Co., Ltd. when and as it cash flows allow as agreed by both parties.
- (b) Included in deposit as of June 30, 2016 and December 31, 2015 is a deposit of RMB12,688,000 to the contractor of the new hospital construction work as the guarantee for fulfillment of obligation of the Group under the construction contract. The deposit will be repaid to the Group after the construction is completed and all Group's obligation has been discharged.
- (c) The Company entered into an agreement with Sichuan Hongji Pharmaceutical Company Limited (四川红济制药有限公司), an independent third party in March 2015 and planned to develop certain business with Sichuan Hongji. The Company placed a deposit of RMB12,000,000 to Sichuan Hongji as a pre-capital contribution. Subsequently, the agreement was cancelled and a supplementary agreement was entered into by Sichuan Hongji, Chengdu Jihong Hospital Company Limited (成都纪红医院有限公司, a wholly owned subsidiary of Sichuan Hongji) and the Company on June 29, 2015. Pursuant to the supplementary agreement, the latter parties agreed to abandon the business plan and the deposit should be repaid by Chengdu Jihong to the Group within 12 months commencing from June 29, 2015, bearing an interest rate of 5% per annum. The amount is guaranteed by the shareholder of Sichuan Hongji.

On July 28, 2015, Chengdu Jihong changed its name to Chengdu Renji Hospital Company Limited.

- (d) In June 2016, the Company entered into an agreement with the Vendor and Wenji Medical Unit. Pursuant to the agreement, the Company has agreed to acquire 51% of the equity in the Guoda Investment from the Vendor and creditworthiness from Wenji Medical Unit. Following completion of the public bidding process which it mandated for the aforementioned transaction, the Company has received the highest bid for the equity in the and creditworthiness as an aggregate consideration of RMB38,096,000, representing RMB17,492,000 for the equity in the and RMB20,604,000 for the creditworthiness. As of June 30, 2016, the transaction of the one-hundred percent of the approval registration with the relevant government authorities in the PRC. The acquisition is substantially completed in August 2016.

8.3.3

2015
B'000 RMB'000
(Audited)

Tea, medicine and general healthcare
service

Pharmaceutical sale

Ancillary hospital service

Management service fee

111,945
42,227
997
5,574
<u>160,743</u>

All the entities generated in the PRC are all located in the Guopai area. The Guopai has a highly diversified patient portfolio, a side from Pingyang Changgeng Hospital Co., Limited, from which the Guopai earn management service fee of RMB6,254,000 and RMB5,574,000 respectively in the month ended June 30, 2016 and 2015, no single patient or client contributed 1% or more of the Guopai's earnings in the period.

8.3.4 Income tax

The income tax expense of the Group for the month ended June 30, 2016 and 2015 is analysed as follows:

	2016	2015
	RMB'000	RMB'000
	(Audited)	(Audited)
Group income tax:		
BPRC corporate income tax	10,344	
Deferred income tax	(612)	
	<u>9,732</u>	

The amount of the Group's profit before income tax differs from the theoretical amount that would arise, in the absence of the PRC, the principal place of the Group's operation, as follows:

	2016	2015
	RMB'000	RMB'000
	(Audited)	(Audited)
Profit before income tax	37,086	
Calculated at the rate of 25%	9,272	
Expense not deductible	460	
Income not subject to tax	B	
Over-position in prior year	B	
Tax loss for which no deferred income tax asset is recognised	B	
	<u>9,732</u>	

The income tax provision of the Group in respect of operation in the PRC has been calculated at the rate of 25% on the estimated taxable profit, based on the existing legislation, interpretation and practice in respect thereof, unless preferential tax rate is applicable.

8.3.5 基本每股收益

(a) Basic earnings per share

The calculation of basic earnings per share is based on profit attributable to ordinary equity holders of the Company of RMB28,207,000 and RMB29,130,000 for the months ended June 30, 2016 and 2015 respectively and the weighted average number of ordinary shares in issue at the end of each reporting period, is calculated as follows:

		2015
		No. of shares (Audited)
Ordinary shares issued at beginning of the period	50,000,000	
Effect of increase of shares	1,423,000	
Weighted average number of ordinary shares at the end of period	51,423,000	

The calculation of earnings per share for the months ended June 30, 2016 is based on 73,040,000 (for the months ended June 30, 2015: 51,423,000) ordinary shares.

(b) Diluted earnings per share

The Company did not have any potential dilutive shares throughout the period. Accordingly, diluted earnings per share are the same as the basic earnings per share.

8.3.6

(a) Capital commitments

	December 31, 2015
	RMB'000
	(Audited)
Contracted but not provided for	
Construction building	36,635
Leasehold improvements	60,529
Property, plant and equipment	10,935
	<u>108,099</u>

(b) Operating lease commitments

The Group lease certain office building and hospital under non-cancellable operating lease agreements. The Group's future aggregate minimum lease payments under non-cancellable operating lease are as follows:

	December 31, 2015
	RMB'000
	(Audited)
Not later than 1 year	28,593
Later than 1 year and not later than 5 years	74,546
Later than 5 years	105,831
	<u>208,970</u>

8.3.7 Dividend

On March 24, 2016, the Board declared a final dividend of RMB18,260,000 for the year ended December 31, 2015 which is calculated based on 73,040,000 issued shares as at December 31, 2015. The proposed dividend is approved by the shareholders at the annual general meeting on June 14, 2016. The dividend is reflected as a dividend payable in the condensed consolidated interim financial information for the interim month ended June 30, 2016.

On March 11, 2015, the Board declared a final dividend of RMB18,480,000 for the year ended December 31, 2014. The proposed dividend is approved by the shareholders' meeting on June 1, 2015 and the Company paid out the dividend on July 23, 2015.

Board of the Board

CHONG Yat Keung
Chairman

Zhejiang, the PRC

August 29, 2016

As of the date of this announcement, the Company's executive directors are Mr. GUAN Weili, Ms. WANG Lianyue and Ms. WANG Hongyue; the non-executive directors are Mr. YANG Yang and Ms. HE Xin; and the independent non-executive directors are Mr. CHONG Yat Keung, Mr. HUANG Zhi and Mr. GOT Chong Key Clevin.